At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 62 enrolled
Drug / intervention
LAM-002A +2 moredrug
Likely dose
LAM-002A 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
In Brief
A Phase 1 clinical trial evaluating LAM-002A, Rituximab, and 1 other intervention for Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic. Completed, enrolled 62 participants across 11 sites.
Detailed Summary
This is a Phase 1 dose-exploration study of LAM-002A administered by mouth in patients with relapsed or refractory B-cell NHL. Safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD),and preliminary anti-tumor activity will be evaluated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedNov 2015
Primary CompletionMar 2020
Study CompletionMar 2023
TodayJul 2026
First PostedNov 3, 2015
Enrollment StartOct 1, 2015
Primary CompletionMar 9, 2020
Study CompletionMar 30, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.7 years ago
Interventions
LAM-002Adrug
25 mg capsules or 50 mg capsules
Rituximabdrug
375 mg/m2 by vein
Atezolizumabdrug
1200 mg by vein